

BIOSEPARATION SYSTEMS FOR GLOBAL BIOPHARMACEUTICAL MARKETS

(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1. Introduction 10

1.1 Statement of Report 10

1.2 About this Report 10

1.3 Objectives 11

1.4 Scope of Report 12

1.5 Methodology 12

1.6 Executive Summary 13

2. Overview 15

2.1 Introduction 15

2.2 Biopharmaceutical Industry Environment 15

2.2.1 Investment in Healthcare Worldwide 15

2.2.2 Diseases and Development of New Biologics 15

2.2.3 High Cost of Development and Manufacturing a Biological 15

2.2.4 Economics and Reimbursement for Biological Therapies 16

2.2.5 Strict Regulation of Biologics Manufacturing 16

2.3 Trends in Bioseparations 16

2.3.1 Single-Use Biomanufacturing Technology is Enabling the Biologics Factory of the Future 16

2.3.2 Emerging and Disruptive Bioprocessing Technologies Have Potential to Reduce Downstream Processing Bottlenecks 17

2.3.3 Asia is Becoming a Global Manufacturing Hub 17

2.3.4 Contract Manufacturing Organizations Offering “Biomanufacturing on Demand” 18

2.3.5 Biosimilars are in Demand Globally 18

2.4 Global Biomanufacturing Demographics 19

2.4.1 Global Biologics Producers 19

2.4.2 Global Biomanufacturing Capacity 21

3. Biologics in the Development Phase 23

3.1 Monoclonal Antibodies 24

3.2 Vaccines 24

3.3 Veterinary Vaccines 25

3.4 Recombinant Proteins and Peptides 25

3.5 Blood Plasma Fractionation 26

3.6 Cell Therapy 26

3.7 Gene Therapy 26

3.8 Antisense 26

4. Bioseparations Products and Systems 27

4.1 Chromatography 27

4.2 Membranes and Filters 27

4.3 Centrifuges 27

4.4 Leading Manufacturers of Bioseparations Products and Systems 28

5. The Biopharmaceutical Manufacturing Process 32

5.1 Upstream Processing 32

5.1.1 Host Cell Lines 32

5.1.2 Bioreactors 33

5.1.3 Productivity Improvements in Upstream Processing 33

5.2 Downstream Processing 33

5.2.1 Remove Insolubles 33

5.2.2 Isolation 33

5.2.3 Capture and Purification 34

5.2.4 Polishing 34

5.3	Application of Bioseparations Products for Downstream Processing	35
5.4	Downstream Process Development	35
5.4.1	Laboratory Development	35
5.4.2	Pilot and Scale Up	36
5.4.3	Manufacturing Scale	36
5.4.4	Process Validation	36
5.4.5	Role of Bioseparations Vendors in Process Development	36
5.5	Good Manufacturing Practices and Regulatory Requirements for Manufacture of Biologicals	37
5.6	Biomanufacturing Cost Considerations	37
5.7	Downstream Bottlenecks	38
6.	Bioseparation Processes Used for Biologics Manufacturing	39
6.1	Separation and Purification of Recombinant Proteins from Mammalian Cells	39
6.1.1	Monoclonal Antibody Therapeutics	39
6.1.2	Recombinant Erythropoietin	40
6.2	Separation and Purification of Recombinant Proteins from Microbial Cell Culture	40
6.2.1	Recombinant Insulin	40
6.3	Vaccine Purification	42
6.3.1	Microbial Vaccines and Toxoids	42
6.3.2	Viral and Capsid Vaccines	42
6.3.3	Polysaccharide Vaccines and Conjugates (Pneumococcal Vaccines)	42
6.3.4	Recombinant Protein Vaccines	43
6.3.5	DNA Vaccines and Gene Therapy	44
6.3.6	Viral Vector Vaccines	44
6.4	Plasma Fractionation	44
6.5	Transgenic Animals and Plants: Emerging Technologies for Producing Biologics	45
6.5.1	Downstream Processing of Transgenically Produced Biologics	46
6.5.2	Specialty Bioseparations Products for Purification of Biologics Produced from Transgenic Animals or Plants	47
7.	Global Bioseparation Market Analysis	48
7.1	The Global Bioseparations Market Size	48
7.2	Global Bioseparations Market Size by Product	48
7.3	Bioseparations Market by Consumables and Equipment	50
8.	The Global Bioseparations Market by Region	52
8.1	North America Bioseparations Market	55
8.1.1	The Market Situation	55
8.1.2	Regulatory	56
8.1.3	Biomanufacturing in North America	56
8.1.4	New Construction and Capacity	57
8.1.5	Blood Plasma Fractionation	57
8.1.6	Vaccines	57
8.1.7	Biosimilars	58
8.2	Western Europe Bioseparations Market	58
8.2.1	Bioseparations Manufacturers in Europe	58
8.2.2	The Market Situation	58
8.2.3	Regulatory	59
8.2.4	Biomanufacturing in Western Europe	59
8.2.5	Biosimilars	61
8.2.6	Vaccines	61
8.2.7	Blood Plasma Fractionation	62
8.3	Asia-Pacific Bioseparations Markets	62
8.3.1	Japanese Bioseparations Market	63
8.3.2	Singaporean Bioseparations Market	65

8.3.3	South Korean Bioseparations Market	66
8.4	BRIC Emerging Countries' Bioseparations Markets	67
8.4.1	Chinese Bioseparations Market	69
8.4.2	Indian Bioseparations Market	72
8.4.3	Brazilian Bioseparations Market	76
8.4.4	Russian Bioseparations Market	78
9.	Competitive Landscape	80
9.1	GE Healthcare Life Sciences	80
9.1.1	Strategy	80
9.1.2	Bioseparations Product Mix and Brands	80
9.1.3	Platforms and Product Groups	81
9.1.4	Process Development and Technical Support	82
9.1.5	New Product Launches	82
9.2	Merck Millipore	83
9.2.1	Strategy	83
9.2.2	Bioseparations Product Mix and Brands	84
9.2.3	Platforms and Product Groups	85
9.2.4	Training and Support	86
9.2.5	New Product Launches	86
9.3	Pall Corporation	87
9.3.1	Strategy	87
9.3.2	Bioseparations Product Mix and Brands	87
9.3.3	Platforms and Product Groups	88
9.3.4	Training and Support	88
9.3.5	New Product Introductions	89
9.4	Sartorius	89
9.4.1	Strategy	89
9.4.2	Bioseparations Product Mix and Brands	90
9.4.3	Platforms and Product Groups	91
9.4.4	Training and Support	91
9.4.5	New Product Launches	92
9.5	3M CUNO	92
9.5.1	Strategy	92
9.5.2	Bioseparations Product Mix and Brands	92
9.5.3	Training and Support	93
10.	Industry Analysis	94
10.1	Recent Industry Developments	94
10.2	Emerging Technologies	95
10.2.1	Simulated Moving Bed Chromatography/Continuous Countercurrent Flow	95
10.2.2	Monolith Chromatography	96
10.2.3	High Performance Tangential Flow	96
10.2.4	Expanded Bed Adsorption Chromatography	97
10.2.5	Novel Affinity Separations for Blood Plasma Fractionation	97
10.3	Gaps and Challenges	97
10.3.1	Downstream Bottlenecks	97
10.3.2	Single-Use Technologies in Downstream Processing	98
10.4	Opportunities	98
10.4.1	Platform Technologies and Turn Key Biomanufacturing	98
10.4.2	Bioseparations for Biologics Produced from Transgenic Animals and Genetically Engineered Plants	98
10.5	Strategic Recommendations	99
10.5.1	Competing in the Bioseparations Market	99
10.5.2	Competing in Emerging and Developing Countries	99

11.	Single-Use Bioseparations Systems and Products	100	
11.1	Drivers and Restrictors for Single Use Technology	100	
11.2	Single-Use Technology for Downstream Purification of Monoclonal Antibodies	101	101
11.3	Single-Use Technology For Vaccine Production	101	
11.4	Single-Use Systems and Skids for Downstream Processing	101	
11.5	Pre-Packed Chromatography Columns for Downstream Processing	102	102
11.6	Single-Use Membrane Absorbers for Downstream Processing	102	
11.7	Single-Use Tangential Flow Ultrafiltration for Downstream Processing	103	103
11.8	Virus Reduction Membranes	104	
11.9	Single-Use Depth Filters for Downstream Processing	105	
11.10	Single-Use Centrifuges for Downstream Processing	105	
12.	Chromatography for Bioseparations	107	
12.1	Chromatography Size and Growth	107	
12.2	Chromatography Market Drivers and Restrictors	107	
12.3	Leading Chromatography Manufacturers	108	
12.4	Principle of Separation	108	
12.5	Liquid Chromatography Media	109	
12.5.1	Ion Exchange	110	
12.5.2	Affinity	110	
12.5.3	Immobilized Metal Ion Chromatography	110	
12.5.4	Hydrophobic Interaction Chromatography	110	
12.5.5	Size Exclusion Chromatography or Gel Filtration	111	
12.5.6	Mixed- or Multi-Mode Chromatography	111	
12.6	Advantages and Disadvantages of Chromatography for Bioseparations	112	112
12.7	Leading Manufacturers of Chromatography for Bioseparations	113	
13.	Filters and Membranes Used for Bioseparations	117	
13.1	Filtration and Membrane Market Size and Growth	117	
13.2	Filtration and Membrane Market Drivers and Restrictors	118	118
13.3	Leading Membrane and Filtration Manufacturers	118	
13.4	Principle of Separation	119	
13.4.1	Normal Flow Filtration	119	
13.4.2	Tangential Flow Filtration of Crossflow	120	
13.5	Membrane and Filter Materials of Construction	120	
13.5.1	Polyethersulfone	120	
13.5.2	Regenerated Cellulose	120	
13.5.3	Cellulose Acetate	120	
13.5.4	Polytetrafluorethylene	120	
13.5.5	Polyvinylidene Difluoride	120	
13.5.6	Nylon	121	
13.5.7	Depth Filtration Media	121	
13.6	Ultrafiltration	121	
13.7	Microfiltration	123	
13.8	Depth Filters	124	
13.9	Membrane Absorbers	126	
13.10	Virus Removal Membranes	126	
13.11	Sterilizing Filters	127	
13.12	Ceramic Membranes and Modules	128	
13.13	Membrane Applications for Biopharmaceutical Manufacturing	129	129
13.13.1	Cell Harvesting and Clarification	129	
13.13.2	Concentration and Diafiltration	129	
13.13.3	Purification	129	
13.13.4	Virus Reduction	129	
13.13.5	Endotoxin Removal and Sterile Filtration	129	

13.13.6	Sterile Filtration	130	
13.14	Advantages and Disadvantages of Membranes and Filters		131
13.14.1	Ultrafiltration	131	
13.14.2	Microfiltration	132	
13.14.3	Depth Filters	132	
13.14.4	Ceramic Membranes	132	
13.14.5	Virus Removal Membranes	132	
14.	Industrial Centrifuges for Downstream Processing		134
14.1	Centrifuge Market Size and Growth	134	
14.2	Principle of Separation	135	
14.3	Centrifuge Types	135	
14.3.1	Disc Stacked Centrifuges	135	
14.3.2	Tubular Bowl Centrifuges	135	
14.3.3	Vertical Basket Centrifuge	136	
14.4	Application of Centrifuges in Downstream Processing		136
14.4.1	Recovery of Extracellular Recombinant Proteins and Monoclonal Antibodies		136
14.4.2	Recovery of Intracellular Recombinant Proteins and Inclusion Bodies		136
14.4.3	Fractionation of Plasma Proteins	136	
14.4.4	Vaccine Production	137	
14.5	Centrifuge Advantages and Disadvantages	137	
14.6	Competition	138	
14.7	Leading Manufacturers and Products		138
14.7.1	Alfa Laval	138	
14.7.2	Alfa Wasserman	138	
14.7.3	Carr Centritech	138	
14.7.4	Celeros Separations	138	
14.7.5	Flottweg Separation Technology	139	
14.7.6	Hitachi Koki Ltd	139	
14.7.7	New Brunswick	139	
14.7.8	Westfalia	139	
15.	Company Profiles		141
15.1	Agilent Technologies	141	
15.2	Alfa Wassermann Separation Technologies	141	
15.3	Applied Biosystems Corporation (Life Technologies)		141
15.4	Asahi Kasei	141	
15.5	Bio-Rad Laboratories	142	
15.6	Carr Centritech	142	
15.7	Celeros	142	
15.8	Dow Chemical Company	142	
15.9	DSM Biologics	143	
15.10	Flottweg Separations Technology	143	
15.11	G-Con Manufacturing	143	
15.12	GEA Westfalia Separator Group	143	
15.13	GE Healthcare Life Sciences	144	
15.14	Hitachi Koki Co. LTD	144	
15.15	Knauer	144	
15.16	Kronlab (YMC Europe)	145	
15.17	Life Technologies	145	
15.18	Meissner Filtration Products, Inc.	147	
15.19	Merck Millipore	147	
15.20	3M Cuno	147	
15.20.1	Overview	148	
15.20.2	Operating Segments	148	

15.20.3	Products	149
15.21	Novasep Life Sciences Manufacturing Solutions	149
15.22	Novavax	150
15.23	NuSep Holdings Ltd	150
15.24	Pall Corporation	150
15.25	ProMetic Life Sciences Inc.	151
15.26	Sartorius Stedim Biotech	151
15.27	SciLog	151
15.28	Spectrum Laboratories	152
15.29	Tarpon Biosystems	152
15.30	Tosoh Bioscience	152
15.31	U.S. Filter Control Systems, Inc.	153
15.32	Waters Corporation	153

INDEX OF TABLES

Table 3.1:	Biologics Market Size and Projected Growth by Therapeutic Class	24
Table 4.1:	Comparison of Chromatography, Filtration and Centrifugation for Downstream Processing	28
Table 4.2:	Leading Bioseparations Manufacturers' Market Share	29
Table 4.3:	Leading Bioseparations Manufacturers' Product Lines	29
Table 4.4:	North American Companies Participating in the Bioseparations Market	30
Table 4.5:	European Companies Participating in the Bioseparations Market	30
Table 4.6:	Asian Companies Participating in the Bioseparations Market	31
Table 5.1:	Optimal Host Cell Line Characteristics	32
Table 7.1:	Bioseparations Systems Market Size and Projected Growth, 2012-2018	48
Table 7.2:	Drivers and Restrictors of the Global Bioseparations Market	48
Table 7.3:	Global Bioseparations Market by Product: Projected Growth 2012-2018	49
Table 7.4:	Global Bioseparations Market: Consumables and Equipment Projected Growth, 2012-2018	50
Table 8.1:	The Global Bioseparations Market by Region: Projected Size, 2012-2018	52
Table 8.2:	North America Bioseparations Market: Projected Size, 2012-2018	55
Table 8.3:	Drivers and Restrictors of the Bioseparation Systems Market in North America	56
Table 8.4:	Largest Biomanufacturing Sites and Capacity in United States	56
Table 8.5:	Major CMOs Manufacturing Capacity in North America	57
Table 8.6:	Western Europe Bioseparations Market: Projected Size, 2012-2018	58
Table 8.7:	Drivers and Restrictors of the Bioseparations Market in Western Europe	59
Table 8.8:	Biomanufacturing Sites and Capacity in Western Europe	60
Table 8.9:	Major CMOs Biomanufacturing Capacity in Western Europe	61
Table 8.10:	Major Vaccine Manufacturing Sites in Western Europe	62
Table 8.11:	Western Europe Blood Fractionation Facilities	62
Table 8.12:	Asia-Pacific Biomanufacturing Market: Projected Size, 2012-2018	63
Table 8.13:	Drivers and Restrictors of the Bioseparations Market in Japan	63
Table 8.14:	Alliances and Manufacturing Capacity of Selected Japanese Biopharmaceutical Companies	64
Table 8.15:	Singaporean Biomanufacturing Capacity	65
Table 8.16:	South Korean Biomanufacturing Capacity	67
Table 8.17:	Emerging Countries' Bioseparations Systems Market Projected by Country 2012-2018	68
Table 8.18:	Chinese Bioseparations Market: Projected Size, 2012-2018	70
Table 8.19:	Drivers and Restrictors of the Bioseparations Market in China	70
Table 8.21:	Indian Bioseparations Market: Projected Size, 2012-2018	72
Table 8.22:	Drivers and Restrictors of the Bioseparations Market in India	73
Table 8.23:	Indian Biomanufacturing Companies and Capacity	75
Table 8.24:	Brazilian Bioseparations Market: Projected Size, 2012-2018	76
Table 8.25:	Drivers and Restrictors of the Bioseparation Systems Market in Brazil	76
Table 8.26:	Russian Bioseparations Market: Projected Size, 2012-2018	78
Table 8.27:	Drivers and Restrictors of the Bioseparation Systems Market in Russia	78

Table 9.1: GE Healthcare Life Sciences Strengths and Weaknesses	81
Table 9.2: GE Healthcare Life Sciences Bioseparations Products and Brands	81
Table 9.3: Merck Millipore Strengths and Weaknesses	84
Table 9.4: Merck Millipore Bioseparations Products and Brands	84
Table 9.5: Merck Millipore Mobius Single-Use Platform	85
Table 9.3: Pall Corporation Strengths and Weaknesses	87
Table 9.4: Pall Corporation Bioseparations Products and Brands	88
Table 9.5: Sartorius Strengths and Weaknesses	90
Table 9.6: Sartorius Bioseparations Products and Brands	90
Table 9.7: 3M Cuno Strengths and Weaknesses	92
Table 9.8: 3M Cuno Bioseparations Products and Brands	93
Table 11.1: Drivers and Restrictors for Single-Use Technology	100
Table 11.2: Single-Use Systems for Clinical Scale Downstream Processing	102
Table 11.3: Pre-Packed Chromatography Columns for Downstream Processing	102
Table 11.4: Single-Use Membrane Absorbers for Downstream Processing	103
Table 11.5: Single-Use Tangential Flow Ultrafiltration for Downstream Processing	104
Table 11.6: Viral Reduction Membranes for Downstream Processing	104
Table 11.7: Single-Use Depth Filters for Downstream Processing	105
Table 11.8: Single-Use Centrifuges for Downstream Processing	106
Table 12.1: Projected Growth for Global Chromatography Market for Bioseparations, 2012-2018	107
Table 12.2: Chromatography Market Drivers and Restrictors	108
Table 12.3: Manufacturers of RP-HPLC Chromatography Media for Bioseparations	109
Table 12.4: Bioseparations by Chromatography Type	112
Table 12.5: Chromatography Advantages and Disadvantages	113
Table 12.6: GE Healthcare Life Sciences Process Scale Chromatography Media and Columns	114
Table 12.7: Merck Millipore Process Scale Chromatography Media and Columns	114
Table 12.8: Pall Corporation Process Scale Chromatography Media and Columns	115
Table 12.9: Life Technologies Applied Biosystems Process Scale Chromatography Media and Columns	115
Table 12.10: Bio-Rad Process Scale Chromatography Media and Columns	116
Table 12.11: Second Tier Competitors' Process Scale Chromatography Media and Columns	116
Table 13.1: Projected Growth of the Global Market for Membranes and Filters for Bioseparations, 2012-2018	117
Table 13.2: Drivers and Restrictors Membranes and Filters of For Bioseparations	118
Table 13.3: Pore Size of Ultrafilters Described by NMWC	122
Table 13.4: Leading Companies' Ultrafiltration Membranes	123
Table 13.5: Leading Companies' Microporous Membranes	124
Table 13.6: Leading Companies' Depth Filters	125
Table 13.7: Leading Companies' Membrane Absorbers	126
Table 13.8: Leading Companies' Virus Removal Membranes	127
Table 13.9: Leading Companies Sterilizing Filters	128
Table 13.10: Application of Membranes and Filters for Biopharmaceutical Manufacturing	131
Table 13.11: Advantages and Disadvantages of Membranes and Filters	133
Table 14.1: Projected Growth of the Global Market for Centrifuges for Bioseparations, 2012-2018	134
Table 14.2: Drivers and Restrictors	134
Table 14.3: Advantages and Disadvantages of Centrifugation for Cell Harvesting and Clarification	137
Table 14.4: Leading Manufacturers' Centrifuges for Downstream Processing	139
Table 14.5: Leading Manufacturer's Centrifuges for Downstream Processing	140

INDEX OF FIGURES

Figure 2.1: Global Distribution of Biomanufacturing Capacity	22
Figure 3.1: Number of Biologicals in Development in the United States	23
Figure 3.2: Pipeline of Biologics by Therapeutic Class	23
Figure 4.1: Leading Bioseparations Manufacturer's Market Share	29
Figure 5.1: The Downstream Process for Purifying Biologicals	34

Figure 6.1: Downstream Isolation and Purification of Monoclonal Antibodies	39
Figure 6.2: Downstream Purification of Insulin Produced by the Intracellular Proinsulin Process	41
Figure 6.3: Downstream Processing of Recombinant Protein Produced from Insect Cells	43
Figure 6.4: Downstream Processing of Plasmid DNA	45
Figure 7.1: Global Bioseparations Market by Product	49
Figure 7.2: Global Bioseparations Market by Product: Projected Growth, 2012-2018	50
Figure 7.3: Global Bioseparations Market: Projected Growth of Consumables and Equipment, 2012-2018	51
Figure 8.1: Global Bioseparations Market by Region, 2013	52
Figure 8.2: Global Bioseparations Systems Market by Region, 2018	53
Figure 8.3: Global Bioseparations Market Projected by Region, 2013-2018	54
Figure 8.4: Global Bioseparations Market: Projected Growth by Region, 2012-2018	54
Figure 8.5: Emerging Countries' Bioseparations Market Share by Country	67
Figure 8.6: Emerging Countries' Bioseparations Market Projected by Country, 2013-2018	68
Figure 8.7: Emerging Countries' Bioseparations Market Projected Growth by Country, 2012-2018	69
Figure 12.1: Global Bioseparations Market for Chromatography by Region 2012	107
Figure 12.2: Process Scale Chromatography Columns	109
Figure 13.1: Global Bioseparation Market for Membranes and Filters by Region, 2012	117
Figure 13.2: Image of a Depth Filter	121
Figure 13.3: Image of a Cross-Section of an Ultrafiltration Membrane	122
Figure 13.4: Image of the Surface of a Microporous Membrane	124
Figure 13.5: Installing Depth Filter Modules for Downstream Processing	125
Figure 13.6: Ceramic Membranes Encapsulated in Stainless Steel Housing	128
Figure 14.1: Global Bioseparations Market for Centrifuges, 2012	134
Figure 14.2: Disc Stack Centrifuge	135
Figure 14.3: Tubular Bowl Centrifuge	136

1. Overview

1.1 Statement of Report

Bioseparations Systems can be categorized into three types: chromatography, membranes/filters, and centrifuges. In this report, each is examined in detail including market size, drivers and restrictors, competitors and technology. In 2012, chromatography will contribute \$1.2 billion to the global bioseparations market, membrane/filters will contribute \$1.1 billion, and centrifuges will contribute \$0.9 billion.

1.2 About this Report

The demand for single use products is increasing and fueling growth of the Global bioseparations market. New biosimilars are driving the increase in global biomanufacturing capacity. Blockbuster biologics are going off patent leaving the market open for development and manufacture of low cost biosimilars. Asian countries of India, Singapore, South Korea and China are fast becoming biomanufacturing hubs producing biosimilars for their large populations and Southeast Asia. Contract manufacturing organizations are increasing, providing biomanufacturing “capacity on demand” for biopharmaceutical and new development stage companies.

The main objectives of this analysis are:

- For the general Bioseparations testing market:
 - The size of the market and distribution between different market segments.
 - The expected growth over the next 5 years within each market segment.
 - A comprehensive overview of the main Bioseparations players. What kind of equipment do they have and what is the capacity of manufacturing.
 - Which sectors in bioseparations for the biopharmaceutical manufacturing area are expected to experience high growth in going forward.
- Identifying viable technology drivers through a comprehensive look at platform technologies for bioseparations Systems for the pharmaceutical industry.
- Understanding the different sectors of bioseparations, looking at a description of the instruments, reagents and supplies marketed by major companies in each segment.
- Obtaining a complete understanding of the individual bioseparations tests, from their basic principles to their clinical applications.
- Discovering feasible market opportunities by identifying high-growth applications in different analytical areas, emphasizing the biggest and expanding markets.
- Focusing on global industry development through an in-depth analysis of the major world markets for bioseparations technology, including growth forecasts.
- Presenting bioseparations market figures regarding the market’s current value, market projections, market share, key players and sector growth rates, using the most current data derived from the global diagnostic industry.

This study contains:

- A detailed analysis of recent trends in the bioseparations marketplace.
- In-depth profiles of the leading companies with bioseparations tools and technologies.
- A forecast for the bioseparations market in the biotechnology and diagnostic industries.
- Views and principles on the bioseparations industry from leading industry experts.
- An analysis of potential new bioseparations applications in the pharmaceutical sector.
- Market predictions and trends analysis concerning U.S. expenditures on bioseparations solutions.
- Projections of bioseparations market sizes for European and Asian markets.
- Analysis of commercial bioseparations business strategies.
- The latest news and merger and acquisition developments in the bioseparations marketplace.
- A comprehensive overview of and insight into bioseparations business strategies.
- An in-depth examination of the subsections of each market segment.

Analysis includes charts and graphs measuring product growth and trends within the marketplace. Company-specific information, including sales figures, product pipeline status and research and development (R&D) trends, is provided. This review will also:

- Assess bioseparations market drivers and bottlenecks from medical and scientific community perspectives.
- Discuss the potential benefits of bioseparations for various sectors of the medical and scientific community.
- Establish the current total market size and future growth of the bioseparations market and analyze the current size and growth of individual segments.
- Provide current and forecasted market shares by company.
- Discuss profit and business opportunities by segment.
- Provide strategic recommendations for near-term business opportunities.
- Assess current commercial uses of the bioseparations market.

The following questions will also be addressed in this analysis:

- What are the near-term business opportunities in the bioseparations market?
- What are the current and forecasted bioseparations market sizes in the U.S., the European Union (E.U.), Japan and other key country markets?
- What are the business models currently used by companies in the bioseparations market?
- How will manufacturers, researchers, physicians and patients influence this market?
- What are the drivers and restraints influencing the bioseparations market?
- What are the technologies used in bioseparations?
- Who holds the proprietary rights to the bioseparations market technology platforms?
- In the U.S., Japan and the E.U., what regulatory processes apply to bioseparations technologies?

The report includes:

- A comprehensive overview of the several categories of bioseparations technology platforms that are or will be revolutionizing the use of diagnostic tests in hospitals.
- A chapter on each of the important bioseparations categories and applications.
- Full descriptions of the technologies involved and how they differ from existing and emerging technologies.
- Analysis of the technological approaches undertaken by various competitors, as well as industry and end-user responses to these products.
- Regulatory issues and legislation affecting the use and marketing of bioseparations products.
- Market forecasts for each category of product, including profiles of selected competitors.

1.3 Objectives

This report provides market revenue size and growth rate from [REDACTED] through [REDACTED] for North America, Europe, Asia-Pacific (Japan, South Korea, Singapore), and the emerging BRIC countries (Brazil, Russia, India, China). It analyzes the competitive landscape including key player's strengths and weaknesses, opportunities, gaps and industry trends. Applications and downstream bottlenecks are identified by separations product type for purification of monoclonal antibodies (MAb), recombinant proteins and peptides, vaccines and plasma fractionation. This report includes a comprehensive analysis of manufacturing capacity organized by biopharmaceutical company, contract manufacturing organization (CMO) and region.

1.4 Scope of the Report

This report covers:

- Single-use products.
- Manufacturing capacity.

- Applications of bioseparations in downstream processing.
- Downstream processing bottlenecks.
- Emerging bioseparations technologies.

1.5 Methodology

The writer of this report holds a M.S. in biochemistry from the University of Nebraska and has many decades of experience in pharmaceutical manufacturing and marketing, and as a medical industry analyst. The editor of this report holds a Ph.D. in biochemistry from the University of Minnesota and has had post-doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He also has many decades of experience in science writing and as a medical industry analyst, as well as extensive experience in senior-level management positions in biotech and medical service companies.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites as well as from annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or the results obtained from the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as from Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly available databases, proprietary databases, direct meetings and personal interviews with key personnel.
- Formulating a study outline with the assigned writer, including the following:
 - Market and product segment grouping and evaluating their relative significance.

- Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting-edge applications.
-
- Identifying the key technology and market trends that drive or affect these markets. Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
-
- Launching a combination of primary research activities, including two levels of questionnaires and executive-direct focused, company-specific and region-specific communications to qualified and experienced senior executives worldwide.
-
- Completing a confirmatory primary research assessment of the report's findings with the assistance of Expert Panel Partners from the industry being analyzed.

The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

1.6 Executive Summary

Biomanufacturing is an expensive and complex industry. The manufacturing process requires scale up of a living system producing a biomolecule, then stringent purification of that biomolecule to ensure safety for administration to humans. Biomolecules produced from recombinant technology are variable in structure depending on the cells used to produce the biologic and the downstream purification process. The manufacturing process must be extensively validated as any changes can actually alter the structure of a protein and affect the biological activity or potency.

The capital investment in constructing a new factory to produce these complex biodrugs ranges from \$ [REDACTED] to \$ [REDACTED]. Reduction of the cost of manufacturing a biological is now a high priority for biopharmaceutical and pharmaceutical companies. Competition in the pharmaceutical and biopharmaceutical industry is increasing as more biologics go off patent, opening the door to new, lower cost biosimilars. Asia is becoming a biomanufacturing hub, with the potential to produce biosimilars at a lower cost, and then export its products to other countries.

Biomanufacturing is in a dynamic state of change. The biomanufacturing plant of the future will be more efficient, have higher throughput and greater flexibility. New single-use technology has reduced the need for high cost capital investment in big stainless steel facilities with [REDACTED] L bioreactors. The biomanufacturing industry is moving toward "plug and play" modules with single use upstream and downstream processing trains. These "plug and play" factories can be operational and cGMP compliant in [REDACTED] to [REDACTED] months, compared to years for a traditional, stainless steel factory.

Bioseparations products and systems are essential in the biomanufacturing of all biologicals. These highly specialized separations systems are integral components of the downstream process. They enable the separation of the target biomolecule from a thick, cellular soup-like material, containing proteins from the culture media and host cells, cellular debris, DNA, bacteria and virus and purification to meet the high purity required for administration of the biodrug to humans. Chromatography, membranes, filters and centrifuges are used in the multitude of steps required to purify a biologic. These high value separation systems provide the highest purity required for human use.

The global market for these high value separations products is growing from \$ [REDACTED] in [REDACTED] to \$ [REDACTED] in [REDACTED] at a compound annual rate of [REDACTED]%. North America and Western Europe account for [REDACTED]% of the global market. A significantly higher growth rate of [REDACTED]% is projected for the Asian markets.

Chromatography is the most costly separations method, and is \$ [REDACTED], or [REDACTED]% of the Bioseparations Product Market. Membranes and filters are \$ [REDACTED] ([REDACTED]% of the market), and centrifuges are \$ [REDACTED] ([REDACTED]% of the market).

The market is dominated by five companies: GE Healthcare Life Sciences, Pall Corporation, Merck Millipore, Sartorius and 3M Cuno. These companies collectively own [REDACTED]% share of the global bioseparations market. There are over [REDACTED] companies who manufacture and distribute separations systems and products globally and are competing for share of this rapidly growing market. Companies in this market are developing new single use products, innovative separations technologies to improve downstream processing, and producing “turn-key” systems with specific bioprocessing platforms. They are focusing marketing and sales efforts in Asia and emerging BRIC countries.

TriMark believes that the global bioseparations market will be driven by a number of key favorable industry trends.

- The demand for single use products is increasing and fueling growth of the global bioseparations market. Single use products have shifted the manufacturing cost structure from capital to operating expense. This is allowing rapid start up of biomanufacturing and reduction of millions of dollars in capital costs for expensive stainless bioreactors, holding tanks, and buffer tanks.
- Asian countries of India, Singapore, South Korea and China are fast becoming biomanufacturing hubs producing biosimilars for their large populations. India and China are increasing healthcare coverage, investing in treatments for chronic diseases and cancer. Singapore is a biomanufacturing center for major pharmaceutical and biopharmaceutical companies, producing biologics for the Southeast Asian market. South Korean is becoming a leader in contract manufacturing as well as production of biosimilars.
- New biosimilars are driving the increase in global manufacturing capacity. Blockbuster biologics are going off patent leaving the market open for development and manufacture of low cost biosimilars. Europe is leading in approval and marketing of biosimilars, followed by the emerging BRIC countries.
- Contract manufacturing organizations are increasing capacity to meet the demand from pharmaceutical and biopharmaceutical companies. CMOs are offering “capacity on demand,” a cost-effective alternative to constructing new or expansion of existing biomanufacturing facilities.
- Bioseparations companies are investing in new innovative technologies for chromatography and membrane filtration making the downstream process more efficient. As these technologies are validated, they will replace existing process trains that have become a bottleneck in large biomanufacturing plants.